

# Echelon Biosciences Inc.

## Human Lysosomal Phospholipase A2, active

E-7000

Support: echelon@echelon-inc.com

### Description:

Human Lysosomal Phospholipase A2 (hLPLA2) with C-terminal 6X-His tag was expressed in HEK 293Tn cells and purified using nickel-NTA chromatography. The 6X-His tag was then removed by TEV protease.

### Properties:

Size – 10 µg

Form – Lyophilized

Storage – Store enzyme at -80 °C

Stability – ≥ 6 months from date of receipt


Please refer to Certificate of Analysis (COA) for lot specific buffer formulation, enzyme purity and enzyme specific activity. Please contact technical support for COA of the current lot.

### Background:

LPLA2 is a calcium-independent PLA2, localized to lysosomes, has an acidic pH optimum, and transacylates lipophilic primary alcohols.<sup>1-3</sup> Belonging to the  $\alpha/\beta$ -hydrolase superfamily, LPLA2 is a water-soluble glycoprotein consisting of a single peptide chain with a molecular weight of 45 kDa. In addition to Phospholipase A2 activity, LPLA2 exhibits esterase activity over a wide pH range,<sup>4</sup> and is measured with nitro-phenylbutyrate as a substrate. LPLA2 is secreted under certain conditions.<sup>5</sup> For example, Alveolar macrophages (AMs) secrete LPLA2 following stimulation by Zymosan. Secreted LPLA2 is taken up by AMs via a mannose receptor and transported into acidic compartments. LPLA2-deficient mouse AMs result in a significant accumulation of glycerol-phospholipid and formation of lamellar inclusion bodies, which are characteristic of cellular phospholipidosis.<sup>6</sup> Thus, LPLA2 may be important in the regulation of phospholipids in those cells. Cationic amphiphilic drugs (CADs) can interact with phospholipids and may lead to a reduction in LPLA2 activity, resulting in cellular phospholipidosis in MDCK cells. This suggests that LPLA2 may play an important role in some forms of CAD-induced phospholipidosis in humans.<sup>7</sup>

### Specific Activity:

Please see COA for lot specific enzyme activity



### References:

1. Abe, A.; Hiraoka, M.; Shayman, J. A., The acylation of lipophilic alcohols by lysosomal phospholipase A2. *J Lipid Res* 2007, 48, (10), 2255-63.
2. Abe, A.; Shayman, J. A., Purification and characterization of 1-O-acylceramide synthase, a novel phospholipase A2 with transacylase activity. *J Biol Chem* 1998, 273, (14), 8467-74.
3. Hiraoka, M.; Abe, A.; Shayman, J. A., Cloning and characterization of a lysosomal phospholipase A2, 1-O-acylceramide synthase. *J Biol Chem* 2002, 277, (12), 10090-9.
4. Abe, A.; Shayman, J. A., The role of negatively charged lipids in lysosomal phospholipase A2 function. *J Lipid Res* 2009, 50, (10), 2027-35.
5. Abe, A.; Kelly, R.; Kollmeyer, J.; Hiraoka, M.; Lu, Y.; Shayman, J. A., The secretion and uptake of lysosomal phospholipase A2 by alveolar macrophages. *J Immunol* 2008, 181, (11), 7873-81.
6. Hiraoka, M.; Abe, A.; Lu, Y.; Yang, K.; Han, X.; Gross, R. W.; Shayman, J. A., Lysosomal phospholipase A2 and phospholipidosis. *Mol Cell Biol* 2006, 26, (16), 6139-48.
7. Abe, A.; Hiraoka, M.; Shayman, J. A., A role for lysosomal phospholipase A2 in drug induced phospholipidosis. *Drug Metab Lett* 2007, 1, (1), 49-53.

### Related Products:

Products	Catalog Number
Antibody	
Purified Anti-LPLA2 Antibody	Z-PLPLA2
Assay	
LPLA2 Inhibitor Screen	K-7000I

Technical Data Sheet Rev. 3.12/04/18 - For research use only. Not intended or approved for diagnostic or therapeutic use.



Echelon Biosciences Inc.

Ph: 866-588-0455

Fax: 801-588-0497

Echelon-inc.com